Antithrombotic treatment for stroke prevention in atrial fibrillation: The Asian agenda

International Journal of Cardiology

Volumn 191, Issue , 2015, Pages 244-253

  Chen, Chen Huan ^a,b   Chen, Mien Cheng ^c   Gibbs, Harry ^d   Kwon, Sun U ^e   Lo, Sidney ^f,g   On, Young Keun ^h   Rosman, Azhari ⁱ   Suwanwela, Nijasri C ^j   Tan, Ru San ^k   Tirador, Louie S ^l   Zirlik, Andreas ^m  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^d ALFRED HOSPITAL   (Australia)

^e University of Ulsan   (South Korea)

^f LIVERPOOL HOSPITAL   (Australia)

^g UNIVERSITY OF NEW SOUTH WALES   (Australia)

^h Samsung Medical Center   (South Korea)

ⁱ NATIONAL HEART INSTITUTE   (Malaysia)

^j CHULALONGKORN UNIVERSITY   (Thailand)

^k DEPARTMENT OF CARDIOLOGY   (Singapore)

^l St Paul's Hospital   (Philippines)

^m UNIVERSITY HEART CENTER FREIBURG BAD KROZINGEN   (Germany)

more..

Author keywords

Antithrombotic; Asia; Atrial fibrillation; Oral anticoagulant; Prevention; Stroke

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN; RIVAROXABAN; THROMBIN INHIBITOR; WARFARIN; FIBRINOLYTIC AGENT;

AGE; ANTICOAGULANT THERAPY; ASIA; ATRIAL FIBRILLATION; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; DISEASE CONTROL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MONITORING; EVIDENCE BASED MEDICINE; HEALTH EDUCATION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY FUNCTION; LOW DRUG DOSE; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK REDUCTION; THROMBOEMBOLISM; ASIAN CONTINENTAL ANCESTRY GROUP; ETHNOLOGY; STROKE; TREATMENT OUTCOME;

ASIA; ASIAN CONTINENTAL ANCESTRY GROUP; ATRIAL FIBRILLATION; FIBRINOLYTIC AGENTS; HUMANS; STROKE; TREATMENT OUTCOME;

EID: 84951274688     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2015.03.369     Document Type: Review

References (104)

1. National Institutes of Health, and National Heart Lung and Blood Institute What is Atrial Fibrillation? Accessed July 2011 at: www.nhlbi.nih.gov/health/dci/Diseases/af/af-what.html
2. European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, A.J. Camm, and et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) Eur. Heart J. 31 2010 2369 2429
3. National Institutes of Health, National Heart Lung and Blood Institute, and Blood Institute What are the Signs and Symptoms of Atrial Fibrillation Accessed July 2011 at: www.nhlbi.nih.gov/health/dci/Diseases/af/af-signs.html
4. L. Friberg, N. Hammar, and M. Rosenqvist Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation Eur. Heart J. 31 2010 967 975
5. T. Vanassche, M.N. Lauw, J.W. Eikelboom, and et al. Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES Eur. Heart J. 36 2015 281-7a
6. P. Wolf, R. Abbott, and W. Kannel Atrial fibrillation as an independent risk factor for stroke: the Framingham Study Stroke 22 1991 983 988
7. A.S. Go, E.M. Hylek, K.A. Phillips, and et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study JAMA 285 2001 2370 2375
8. J. Heeringa, D.A. van der Kuip, A. Hofman, and et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study Eur. Heart J. 27 2006 949 953
9. D. Conen, U.B. Tedrow, A. Koplam, R.J. Glynn, J.E. Buring, and C.M. Albert Influence of systolic and diastolic blood pressure on the risk of incident atrial fibrillation in women Circulation 119 2009 2146 2152
10. V. Fuster, L.E. Rydén, and D.S. Cannom American College of Cardiology Foundation/American Heart Association Task Force 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines Circulation 123 2011 e269 e367
11. N. Wanahita, F.H. Messerli, S. Bangalore, A.S. Gami, V.K. Domers, and J.S. Steinberg Atrial fibrillation and obesity - results of a meta-analysis Am. Heart J. 155 2008 310 315
12. H.F. Tse, Y.J. Wang, M. Ahmed Ai-Abdullah, and et al. Stroke prevention in atrial fibrillation - an Asian stroke perspective Heart Rhythm. 10 2013 1082 1088
13. E. Kodani, and H. Atarashi Prevalence of atrial fibrillation in Asia and the world J. Arrhythm. 28 2012 330 337
14. C.E. Chiang, K.L. Wang, and G.Y. Lip Stroke prevention in atrial fibrillation: an Asian perspective Thromb. Haemost. 111 2014 789 797
15. D.E. Singer, G.W. Albers, and J.E. Dalen American College of Chest Physicians Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest 133 Suppl. 6 2008 546S 592S
16. A.S. Go The epidemiology of atrial fibrillation in elderly persons: the tip of the iceberg Am. J. Geriatr. Cardiol. 14 2005 56 61
17. R. Pisters, D.A. Lane, F. Marin, A.J. Camm, and G.Y. Lip Stroke and thromboembolism in atrial fibrillation Circ. J. 76 2012 2289 2304
18. C. Steger, A. Pratter, M. Martinek-Bregel, and et al. Stroke patients with atrial fibrillation have a worse prognosis than patients without: data from the Austrian Stroke registry Eur. Heart J. 25 2004 1734 1740
19. H.S. Jorgensen, H. Nakayama, J. Reith, and et al. Acute stroke with atrial fibrillation. The Copenhagen Stroke Study Stroke 27 1996 1765 1769
20. C. Marini, F. De Santis, S. Sacco, and et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study Stroke 36 2005 1115 1119
21. D.J. Gladstone, E. Bui, J. Fang, and et al. Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated Stroke 40 2009 235 240
22. S. Penado, M. Cano, O. Acha, J.L. Hernández, and J.A. Riancho Atrial fibrillation as a risk factor for stroke recurrence Am. J. Med. 114 2003 206 210
23. E.J. Benjamin, P.A. Wolf, R.B. D'Agostino, H. Silbershatz, W.B. Kannel, and D. Levy Impact of atrial fibrillation on the risk of death: the Framingham Heart Study Circulation 98 1998 946 952
24. M.H. Kim, S.S. Johnston, B.C. Chu, M.R. Dalal, and K.L. Schulman Estimation of total incremental health care costs in patients with atrial fibrillation in the United States Circ. Cardiovasc. Qual. Outcomes 4 2011 313 320
25. S.M. Evers, J.N. Struijs, A.J. Ament, and et al. International comparison of stroke cost studies Stroke 35 2004 1209 1215
26. D.A. Cadilhac, R. Carter, A.G. Thrift, and et al. Estimating the long-term costs of ischemic and hemorrhagic stroke for Australia: new evidence derived from the North East Melbourne Stroke Incidence Study (NEMESIS) Stroke 40 2009 915 921
27. S.J. Lim, H.J. Kim, C.M. Nam, and et al. Socioeconomic costs of stroke in Korea: estimated from the Korea National Health Insurance Claims Database J. Prev. Med. Public Health 42 2009 251 260
28. Y.L. Wang, D. Wu, X. Liao, and et al. Burden of stroke in China Int. J. Stroke 2 2007 211 213
29. Japan Preventive Association of Life-Style Related Disease Surveys of Cerebral Hemorrhage (2007) Accessed July 2014 at: www.seikatsusyukanbyo.com/statistics/2009/09/19-1005.php
30. J. Oldgren, J.S. Healey, and M. Ezekowitz RE-LY Atrial Fibrillation Registry Investigators Variations in etiology and management of atrial fibrillation in a prospective registry of 15,400 emergency department patients in 46 countries: the RE-LY AF registry Circulation 129 2014 1568 1576
31. P.T. Onundarson, G. Thorgeirsson, E. Jonmundsson, N. Sigfusson, and T. Hardarson Chronic atrial fibrillation-epidemiologic features and 14 year follow-up: a case control study Eur. Heart J. 8 1987 521 527
32. T. Nakayama, C. Date, T. Yokoyama, N. Yoshiike, M. Yamaguchi, and H. Tanaka A 15.5-year follow-up study of stroke in a Japanese provincial city. The Shibata Study Stroke 28 1997 45 52
33. K.L. Chien, T.C. Su, H.C. Hsu, and et al. Atrial fibrillation prevalence, incidence and risk of stroke and all-cause death among Chinese Int. J. Cardiol. 139 2010 173 180
34. Y. Guo, G. YH Lip, and S. Apostolakis The unmet need of stroke prevention in atrial fibrillation in the far East and South East Asia Malays J. Med. Sci. 19 2012 1 7
35. J.S. Healey, J. Oldgren, A. Parekh, and et al. RE-LY Atrial Fibrillation Registry Investigators, Global variation in the etiology and management of atrial fibrillation: results from a global atrial fibrillation registry European Society of Cardiology 2011 Oral presentation on 28 August 2011 at the European Society of Cardiology Congress 27-31 August 2011 Paris, France Accessed on 14 October 2014 at: http://www.escardio.org/congresses/esc-2011/congress-reports/Pages/711-6-AF-registry-global.aspx
36. C.S. Leung, and K.M. Tam Antithrombotic treatment of atrial fibrillation in a regional hospital in Hong Kong Hong Kong Med. J. 9 2003 179 185
37. L.J. Lin, M.H. Cheng, C.H. Lee, D.C. Wung, C.L. Cheng, and Y.H. Kao Yang Compliance with antithrombotic prescribing guidelines for patients with atrial fibrillation - a nationwide descriptive study in Taiwan Clin. Ther. 30 Sep 2008 1726 1736
38. G.Y. Lip, C.M. Brechin, and D.A. Lane The global burden of atrial fibrillation and stroke: a systematic review of the epidemiology of atrial fibrillation in regions outside North America and Europe Chest 142 2012 1489 1498
39. B.F. Gage, A.D. Waterman, W. Shannon, M. Boechler, M.W. Rich, and M.J. Radford Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation JAMA 285 2001 2864 2870
40. G.Y. Lip, R. Nieuwlaat, R. Pisters, D.A. Lane, and H.J. Crijns Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation Chest 137 2010 263 272
41. J.B. Olesen, G.Y. Lip, M.L. Hansen, P.R. Hansen, and et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study BMJ 342 2011 d124
42. T. Komatsu, H. Tachibana, Y. Sato, and et al. Relationship between CHADS2 score and ischemic stroke during rhythm control therapy for paroxysmal atrial fibrillation Int. Heart J. 51 2010 24 29
43. T. Komatsu, Y. Sato, M. Ozawa, and et al. Comparison between CHADS2 and CHA2DS2-VASc score for risk stratification of ischemic stroke in Japanese patients with non-valvular paroxysmal atrial fibrillation not receiving anticoagulant therapy Int. Heart J. 55 2014 119 125
44. A.J. Camm, G.Y. Lip, and R. De Caterina ESC Committee for Practice Guidelines (CPG) 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association Eur. Heart J. 33 2012 2719 2747
45. R. Pisters, D.A. Lane, R. Nieuwlaat, C.B. de Vos, H.J. Crijns, and G.Y. Lip A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey Chest 138 2010 1093 1100
46. S. Ogawa, K. Aonuma, D. Huang, and et al. Fact-finding survey of antithrombotic treatment for prevention of cerebral and systemic thromboembolism in patients with non-valvular atrial fibrillation in 9 countries of the Asia-Pacific region J. Arrhythm. 28 2012 41 55
47. A.G. Thrift, H.M. Dewey, J.W. Sturm, and et al. Incidence of stroke subtypes in the North East Melbourne Stroke Incidence Study (NEMESIS): differences between men and women Neuroepidemiology 32 2009 11 18
48. L.F. Zhang, J. Yang, Z. Hong, and et al. Proportion of different subtypes of stroke in China Stroke 34 2003 2091 2096
49. P.H. Chau, J. Woo, W.B. Goggins, and et al. Trends in stroke incidence in Hong Kong differ by stroke subtype Cerebrovasc. Dis. 31 2011 138 146
50. C.R. Gross, C.S. Kase, J.P. Mohr, S.C. Cunningham, and W.E. Baker Stroke in south Alabama: incidence and diagnostic features - a population based study Stroke 15 1984 249 255
51. J. Sivenius, O.P. Heinonen, K. Pyörälä, J. Salonen, and P. Riekkinen The incidence of stroke in the Kuopio area of East Finland Stroke 16 1985 188 192
52. C.J. van Asch, M.J. Luitse, G.J. Rinkel, I. van der Tweel, A. Algra, and C.J. Klijn Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis Lancet Neurol. 9 2010 167 176
53. Y.M. Song, J. Sung, G.D. Smith, and S. Ebrahim Blood pressure, haemorrhagic stroke, and ischaemic stroke: the Korean National Prospective Occupational Cohort Study BMJ 328 2004 831 836
54. O.Y. Bang, K.S. Hong, J.H. Heo, and et al. New oral anticoagulants may be particularly useful for Asian stroke patients J. Stroke 16 2014 73 80
55. G.Y. Lip, H.J. Lin, H.C. Hsu, and et al. Comparative assessment of the HAS-BLED score with other published bleeding risk scoring schemes, for intracranial haemorrhage risk in a non-atrial fibrillation population: the Chin-Shan Community Cohort Study Int. J. Cardiol. 168 2013 1832 1836
56. E. Dardiotis, M. Dardioti, G. Xiromerisiou, K. Paterakis, K. Fountas, and G.M. Hadjigeorgiou Genetic susceptibility to primary intracerebral haemorrhage Eur. Neurol. Rev. 4 2009 44 48
57. L.S. Liu, E.S. Caguioa, C.G. Park, and et al. Asia-Pacific Consensus Conference on Stroke Prevention in Hypertensive Patients. Reducing stroke risk in hypertensive patients: Asian Consensus Conference recommendations Int. J. Stroke 1 2006 150 157
58. M.J. Rieder, A.P. Reiner, and B.F. Gage Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose N. Engl. J. Med. 352 2005 2285 2293
59. S.C. Lee, S.S. Ng, and J. Oldenburg Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population Clin. Pharmacol. Ther. 79 2006 197 205
60. A.Y. Shen, J.F. Yao, S.S. Brar, M.B. Jorgensen, and W. Chen Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation J. Am. Coll. Cardiol. 50 2007 309 315
61. M. Hori, S.J. Connolly, and J. Zhu RE-LY Investigators Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation Stroke 44 2013 1891 1896
62. A.K. Kakkar, I. Mueller, and J.P. Bassand GARFIELD Registry Investigators Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry PLoS One 8 2013 e63479
63. S. Goto, S. Oh, F. Cools, and et al. GARFIELD Investigators. Regional differences in use of antithrombotic therapy for stroke prevention in atrial fibrillation and associated outcomes: European and Asian insights Eur. Heart J. 34 Suppl 1 2013 790 (P4277 2 September 2013)
64. S. Goto, I. Mueller, and D.A. Fitzmaurice GARFIELD Investigators Regional differences in the use of antithrombotic therapy for stroke prevention in atrial fibrillation: European and Asian insights from the Global Anticoagulant Registry in the FIELD (GARFIELD) Eur. Heart J. 33 Abstract suppl 2012 685 (A4043 28 August 2012)
65. JCS Joint Working Group Guidelines for pharmacotherapy of atrial fibrillation (JCS 2008): digest version Circ. J. 74 2010 2479 2500
66. R.G. Hart, L.A. Pearce, and M.I. Aguilar Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation Ann. Intern. Med. 146 2007 857 867
67. G.Y. Lip, R.G. Hart, and D.S. Conway Antithrombotic therapy for atrial fibrillation BMJ 325 2002 1022 1025
68. The ACTIVE Writing Group Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial Lancet 367 2006 1903 1912
69. D.S. Budnitz, M.C. Lovegrove, N. Shehab, and C.L. Richards Emergency hospitalizations for adverse drug events in older Americans N. Engl. J. Med. 365 2011 2002 2012
70. E.M. Hylek, C. Evans-Molina, C. Shea, L.E. Henault, and S. Regan Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation Circulation 115 2007 2689 2696
71. C. Perret-Guillaume, and D.G. Wahl Low-dose warfarin in atrial fibrillation leads to more thromboembolic events without reducing major bleeding when compared to adjusted-dose - a meta-analysis Thromb. Haemost. 91 2004 394 402
72. T. Mavrakanas, and H. Bounameaux The potential role of new oral anticoagulants in the prevention and treatment of thromboembolism Pharmacol. Ther. 130 2011 46 58
73. S.J. Connolly, M.D. Ezekowitz, and S. Yusuf RE-LY Steering Committee and Investigators Dabigatran versus warfarin in patients with atrial fibrillation N. Engl. J. Med. 361 2009 1139 1151
74. S.J. Connolly, M.D. Ezekowitz, S. Yusuf, P.A. Reilly, L. Wallentin, and Randomized Evaluation of Long-Term Anticoagulation Therapy Investigators Newly identified events in the RE-LY trial N. Engl. J. Med. 363 2010 1875 1876
75. M.R. Patel, K.W. Mahaffey, and J. Garg ROCKET AF Investigators Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N. Engl. J. Med. 365 2011 883 891
76. C.B. Granger, J.H. Alexander, and J.J. McMurray ARISTOTLE Committees and Investigators Apixaban versus warfarin in patients with atrial fibrillation N. Engl. J. Med. 365 2011 981 992
77. H. Heidbuchel, P. Verhamme, M. Alings, and et al. European Heart Rhythm Association practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation Europace 15 2013 625 651
78. J.S. Healey, J. Eikelboom, L. Wallentin, and et al. Effect of age and renal function on the risks of stroke and major bleeding with dabigatran compared to warfarin: an analysis from the RE-LY study J. Am. Coll. Cardiol. 55 2010 A4. E37 (Suppl.)
79. Z. Hijazi, S.H. Hohnloser, J. Oldgren, and et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis Circulation 129 2014 961 970
80. K.A. Fox, J.P. Piccini, D. Wojdyla, and et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment Eur. Heart J. 32 2011 2387 2394
81. S.H. Hohnloser, Z. Hijazi, L. Thomas, and et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial Eur. Heart J. 33 2012 2821 2830
82. Bristol-Myers Squibb Company ELIQUIS® (apixaban) Tablets for Oral Use. Full Prescribing Information March 2014 Bristol-Myers Squibb Company Princeton, NJ, USA (Accessed on 29.07.14 at: http://packageinserts.bms.com/pi/pi-eliquis.pdf)
83. Janssen Pharmaceuticals Xarelto® (rivaroxaban) Tablets, for Oral Use. Full Prescribing Information August 2013 Janssen Pharmaceuticals Titusville, NJ, USA (Accessed on 05.09.13 at www.xareltohcp.com/sites/default/files/pdf/xarelto-0.pdf)
84. Boehringer Ingelheim Pharmaceuticals Inc. Pradaxa® (Dabigatran Etexilate Mesylate) Capsules for Oral Use. Full Prescribing Information April 2013 Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, CT, USA (Accessed on 05.09.13 at: http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing Information/PIs/Pradaxa/Pradaxa.pdf)
85. S. Schulman, C. Kearon, A.K. Kakkar RE-MEDY Trial Investigators, and RE-SONATE Trial Investigators Extended use of dabigatran, warfarin, or placebo in venous thromboembolism N. Engl. J. Med. 368 2013 709 718
86. K. Uchino, and A.V. Hernandez Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials Arch. Intern. Med. 172 2012 397 402
87. J.L. Mega, E. Braunwald, and S.D. Wiviott ATLAS ACS 2-TIMI 51 Investigators Rivaroxaban in patients with a recent acute coronary syndrome N. Engl. J. Med. 366 2012 9 19
88. L. Wallentin, S. Yusuf, and M.D. Ezekowitz RE-LY investigators Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial Lancet 376 2010 975 983
89. J.P. Piccini, A.S. Hellkamp, and Y. Lokhnygina ROCKET AF Investigators Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial J. Am. Heart Assoc. 3 2014 e000521
90. L. Wallentin, R.D. Lopes, and M. Hanna Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Investigators Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation Circulation 127 2013 2166 2176
91. K.S. Wong, D.Y. Hu, and A. Oomman Executive Steering Committee and the ROCKET AF Study Investigators Rivaroxaban for stroke prevention in East Asian patients from the ROCKET AF trial Stroke 45 2014 1739 1747
92. C.T. Ruff, R.P. Giugliano, E. Braunwald, and et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials Lancet 383 2013 955 962
93. M. Hori, M. Matsumoto, and N. Tanahashi J-ROCKET AF study investigators Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation - the J-ROCKET AF study Circ. J. 76 2012 2104 2111
94. A.L. Dans, S.J. Connolly, L. Wallentin, and et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial Circulation 127 2013 634 640
95. C.T. Ruff, R.P. Giugliano, E. Braunwald, and et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials Lancet 383 2014 955 962
96. S.J. Connolly, J. Eikelboom, and C. Joyner AVERROES Steering Committee and Investigators Apixaban in patients with atrial fibrillation N. Engl. J. Med. 364 2011 806 817
97. H. Bounameaux, and G. Reber New oral antithrombotics: a need for laboratory monitoring. Against J. Thromb. Haemost. 8 2010 627 630
98. E.S. Eerenberg, P.W. Kamphuisen, M.K. Sijpkens, J.C. Meijers, H.R. Buller, and M. Levi Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects Circulation 124 2011 1573 1579
99. D. Lakkireddy, Y.M. Reddy, L. Di Biase, and et al. Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry J. Am. Coll. Cardiol. 59 2012 1168 1174
100. Janssen Pharmacauticals, Inc. An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin k antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention Accessed July 2014 at: http://clinicaltrials.gov/show/NCT01830543
101. G.Y. Lip, K. Huber, and F. Andreotti European Society of Cardiology Working Group on Thrombosis Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/stenting Thromb. Haemost. 103 2010 13 28
102. J.S. Paikin, D.S. Wright, M.A. Crowther, S.R. Mehta, and J.W. Eikelboom Triple antithrombotic therapy in patients with atrial fibrillation and coronary artery stents Circulation 121 2010 2067 2070
103. M. Moser, C.B. Olivier, and C. Bode Triple antithrombotic therapy in cardiac patients: more questions than answers Eur. Heart J. 35 2014 216 223
104. W.J. Dewilde, T. Oirbans, and F.W. Verheugt WOEST study investigators Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial Lancet 381 2013 1107 1115